Chevy Chase Trust Holdings LLC Buys 40,219 Shares of Illumina, Inc. (NASDAQ:ILMN)

Chevy Chase Trust Holdings LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 8.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 526,414 shares of the life sciences company's stock after purchasing an additional 40,219 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.33% of Illumina worth $70,345,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. CX Institutional bought a new stake in shares of Illumina during the third quarter valued at approximately $218,000. Creative Planning increased its holdings in shares of Illumina by 3.3% in the 3rd quarter. Creative Planning now owns 16,679 shares of the life sciences company's stock worth $2,175,000 after purchasing an additional 535 shares in the last quarter. Beech Hill Advisors Inc. raised its stake in shares of Illumina by 30.2% in the third quarter. Beech Hill Advisors Inc. now owns 7,699 shares of the life sciences company's stock worth $1,004,000 after purchasing an additional 1,784 shares during the last quarter. Probity Advisors Inc. bought a new position in shares of Illumina during the third quarter valued at $239,000. Finally, nVerses Capital LLC purchased a new stake in shares of Illumina during the third quarter valued at $65,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of ILMN stock traded up $0.81 on Tuesday, hitting $101.05. 2,919,076 shares of the stock traded hands, compared to its average volume of 2,421,951. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 52 week low of $99.33 and a 52 week high of $156.66. The firm has a 50 day simple moving average of $131.80 and a two-hundred day simple moving average of $134.75. The firm has a market cap of $16.03 billion, a price-to-earnings ratio of -13.16 and a beta of 1.10.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. As a group, equities research analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ILMN shares. Barclays lowered Illumina from an "equal weight" rating to an "underweight" rating and decreased their target price for the stock from $130.00 to $100.00 in a research report on Monday, February 10th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and lowered their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Royal Bank of Canada cut their target price on shares of Illumina from $250.00 to $247.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Morgan Stanley lowered their price target on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. Finally, UBS Group lifted their price objective on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $159.45.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.